Date: 2011-08-25
Type of information: Fundraising
Company: Mission Therapeutics (UK)
Investors: Sofinnova Partners (France) - Imperial Innovations (UK) - SR One (UK) - Roche Venture Fund (Switzerland)
Amount: £6 million
Funding type: series A round
Planned used:
Others: A team led by Professor Stephen Jackson together with Cancer Research Technology (Cancer Research UK’s commercial arm) and the University of Cambridge has announced the launch of MISSION Therapeutics Ltd, with Series A funding from a top venture capital syndicate. The new spin-out company will translate cutting-edge cell biology research on DNA repair from Professor Jackson’s laboratory at the Gurdon Institute, University of Cambridge, into drugs that will markedly improve the management of life-threatening diseases, particularly cancer. The company will be based at the Babraham Research Campus, Cambridge, UK.
MISSION Therapeutics is developing a broad platform of technologies for the discovery and development of first-in-class drugs targeting enzymes involved in cancer and other diseases. The company will predominantly exploit new and exciting research on ubiquitin pathways that control cellular responses to DNA damage.
Therapeutic area: Cancer - Oncology
